Navigation Links
Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
Date:6/6/2011

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Dr. Bradley Monk of the Creighton University School of Medicine presented a new gynecologic cancer study at the 2011 American Society of Clinical Oncology (ASCO) Annual Symposium, June 5th in Chicago, Illinois.  The study, titled, Acquired Drug Resistance in Gynecologic Cancer Detected by an In Vitro Assay, begins to answer the question of whether ChemoFx® Drug Response Marker test results taken in the primary setting can be utilized for predicting chemotherapeutic response in the recurrent setting.

To evaluate changes in chemosensitivity, ChemoFx® testing was performed on 30 patient specimens in both the primary and recurrent setting.  Test results were then analyzed to observe the development of resistance to commonly-utilized treatments for recurrent gynecologic cancers.  A significant shift towards resistance was found in the agents carboplatin and paclitaxel, but a significant shift was not observed in other agents studied.  The shift in response for carboplatin and paclitaxel may be attributed to a combination of the two agents being a NCCN® Guideline-recommended first-line therapy for primary ovarian cancer patients.

Though this shift towards resistance should be taken into consideration if a metastatic specimen is available for reanalysis, ChemoFx® results for agents not commonly used as first-line therapies were consistent in both the primary and recurrent setting.  This supports the utility of marker results obtained in the primary setting for assisting in treatment decisions when tissue is not available at the time of recurrence.

"This study suggests that ChemoFx® is able to parallel the clinical portion of ovarian cancer treatment that is associated with predicting which drugs are active in targeting optimal chemotherapy," says Dr. Bradley Monk, Professor in the division of Gynecological Oncology at Creighton University School of Me
'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
2. Applied Precision Announces New Products for Life Sciences Microscopy at the 110th American Society for Microbiology Meeting in San Diego, CA, May 23-26th.
3. Precision Bearing Technologies Featured at Atlantic Design & Manufacturing Show
4. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
5. Applied Precisions Mobile Imaging Lab Hits the Road for a Cross-Country Journey
6. Clinical Experts Detail How They Use Varians TrueBeam™ Technology to Improve the Precision and Speed of Cancer Treatments
7. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
8. Applied Precision Installs a Record Four New DeltaVision OMX Super-Resolution Imaging Systems in Eight Weeks
9. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
(Date:9/22/2014)... 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... 2014 ended July 31, 2014 on Monday, September 29 before ... the results at 11:00 AM ET. Participating in the call ... A. Krakauer , President and CEO; Jorgen B. Hansen ... , Senior Vice President, CFO and Treasurer; and Seth ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Inovio ... today it has initiated a phase I clinical ... will evaluate the safety, tolerability, and immunogenicity of ... (HPV-6), which causes most aerodigestive cancers. ... throat, vocal cords, and parts of the esophagus ...
Breaking Medicine Technology:Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
(Date:9/22/2014)... (September 22, 2014) McMaster scientists have found that ... class of antibiotics. , Although dozens of antibiotics ... how a certain part of bacteria are created, and ... , The discovery is important as there is ... the cures for infections ineffective. The World Health Organization ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This Flash ... on stakeholder management needs for the Prostate Cancer market. ... Experts on stakeholder strategies for any launching Prostate Cancer ... of differentiation within an increasingly crowded market , ... The impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... Bronson Gray HealthDay Reporter ... pregnant woman wonders: What can I do to help ensure ... supplements as prescribed may play a role in reducing the ... The researchers found that mothers of children with autism ... and during pregnancy than those whose children seem to be ...
Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... , , , ... Carefx Corporation , a leading provider of interoperable workflow solutions ... one of its clients, the Louisiana Rural Health Information Exchange (LARHIX), was ... Information Executives , a top healthcare information technology magazine. , ...
... , , LAKE ... ), a leading global specialty pharmaceutical and medication delivery company, today ... sales for the quarter were $957 million, and adjusted* diluted earnings ... described later in this press release and the attached schedules.) , ...
... , PITTSBURGH, July 29 Mylan Inc. ... its executive management team. The changes, which reflect internal promotions and ... , Heather Bresch has been promoted to president. ... leadership responsibilities related to the day-to-day operations of the company. She ...
... , , , ... WPI ), a leader in generic and specialty branded pharmaceuticals, today ... Excluding special items as detailed in the reconciliation table below, adjusted ... per diluted share, an increase of $15.8 million or 29 percent. ...
... , , SAFETY ... Prevention Specialist, like many, did not start out with a drug-free ... fought his own battle with substance abuse that ended with his ... , After successfully completing treatment at Narconon, John decided ...
... ... are delighted to announce their partnership to better meet the needs of the autism community in ... ... and AutismOne are delighted to announce their partnership to better meet the needs of ...
Cached Medicine News:Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 3Health News:Hospira Reports Second-Quarter 2009 Results 2Health News:Hospira Reports Second-Quarter 2009 Results 3Health News:Hospira Reports Second-Quarter 2009 Results 4Health News:Hospira Reports Second-Quarter 2009 Results 5Health News:Hospira Reports Second-Quarter 2009 Results 6Health News:Hospira Reports Second-Quarter 2009 Results 7Health News:Hospira Reports Second-Quarter 2009 Results 8Health News:Hospira Reports Second-Quarter 2009 Results 9Health News:Hospira Reports Second-Quarter 2009 Results 10Health News:Hospira Reports Second-Quarter 2009 Results 11Health News:Hospira Reports Second-Quarter 2009 Results 12Health News:Hospira Reports Second-Quarter 2009 Results 13Health News:Hospira Reports Second-Quarter 2009 Results 14Health News:Hospira Reports Second-Quarter 2009 Results 15Health News:Hospira Reports Second-Quarter 2009 Results 16Health News:Hospira Reports Second-Quarter 2009 Results 17Health News:Hospira Reports Second-Quarter 2009 Results 18Health News:Hospira Reports Second-Quarter 2009 Results 19Health News:Hospira Reports Second-Quarter 2009 Results 20Health News:Hospira Reports Second-Quarter 2009 Results 21Health News:Hospira Reports Second-Quarter 2009 Results 22Health News:Hospira Reports Second-Quarter 2009 Results 23Health News:Hospira Reports Second-Quarter 2009 Results 24Health News:Hospira Reports Second-Quarter 2009 Results 25Health News:Hospira Reports Second-Quarter 2009 Results 26Health News:Hospira Reports Second-Quarter 2009 Results 27Health News:Hospira Reports Second-Quarter 2009 Results 28Health News:Mylan Announces Enhancements to Executive Management Team 2Health News:Mylan Announces Enhancements to Executive Management Team 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 5
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: